These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 11161858)

  • 1. p53 mutation is infrequent in clear cell carcinoma of the ovary.
    Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
    Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis.
    Hsueh C; Wang H; Gonzalez-Crussi F; Lin JN; Hung IJ; Yang CP; Jiang TH
    Mod Pathol; 2002 Jun; 15(6):606-10. PubMed ID: 12065773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of p53 is not a feature of ovarian granulosa cell tumors.
    Liu FS; Ho ES; Lai CR; Chen JT; Shih RT; Yang CH; Tsao CM
    Gynecol Oncol; 1996 Apr; 61(1):50-3. PubMed ID: 8626117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 protein expression and gene analysis in clear cell adenocarcinoma of the vagina and cervix.
    Waggoner SE; Anderson SM; Luce MC; Takahashi H; Boyd J
    Gynecol Oncol; 1996 Mar; 60(3):339-44. PubMed ID: 8774636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.
    Leitao MM; Soslow RA; Baergen RN; Olvera N; Arroyo C; Boyd J
    Gynecol Oncol; 2004 May; 93(2):301-6. PubMed ID: 15099937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma.
    Kim JW; Cho YH; Kwon DJ; Kim TE; Park TC; Lee JM; Namkoong SE
    Gynecol Oncol; 1995 May; 57(2):199-204. PubMed ID: 7729734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.
    Liu FS; Kohler MF; Marks JR; Bast RC; Boyd J; Berchuck A
    Obstet Gynecol; 1994 Jan; 83(1):118-24. PubMed ID: 8272291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distant metastases in ovarian cancer: association with p53 mutations.
    Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE
    Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
    Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
    Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An abundance of p53 null mutations in ovarian carcinoma.
    Skilling JS; Sood A; Niemann T; Lager DJ; Buller RE
    Oncogene; 1996 Jul; 13(1):117-23. PubMed ID: 8700537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
    Kowalski LD; Kanbour AI; Price FV; Finkelstein SD; Christopherson WA; Seski JC; Naus GJ; Burnham JA; Kanbour-Shakir A; Edwards RP
    Cancer; 1997 Apr; 79(8):1587-94. PubMed ID: 9118043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of p53 gene in gastric carcinoma in Taiwan.
    Wang JY; Lin SR; Hsieh JS; Hsu CH; Huang YS; Huang TJ
    Anticancer Res; 2001; 21(1B):513-20. PubMed ID: 11299797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
    Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
    Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation between p53 gene mutation and protein expression in 30 cases of human lung cancer].
    Zhang J; Zheng J; Fang W
    Zhonghua Yi Xue Za Zhi; 1998 Nov; 78(11):846-9. PubMed ID: 11038779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
    Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
    Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis.
    Kawasaki H; Ogura T; Yokose T; Nagai K; Nishiwaki Y; Esumi H
    Hum Pathol; 2001 Oct; 32(10):1043-9. PubMed ID: 11679937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.
    Kohler MF; Kerns BJ; Humphrey PA; Marks JR; Bast RC; Berchuck A
    Obstet Gynecol; 1993 May; 81(5 ( Pt 1)):643-50. PubMed ID: 8469448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.